U.S. Food and Drug Administration Grants Fast Track Designation to Three Passage Bio Gene Therapy Candidates Targeting Rare CNS Disorders

PHILADELPHIA, March 8, 2021 (GLOBE NEWSWIRE) —  Passage Bio, Inc., (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous systemThe central nervous system (CNS) is made up of the brain and the spinal cord. (CNS) disorders, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s three lead investigational gene therapies: PBGM01 for the treatment of GM1 gangliosidosis (GM1), PBFT02 for frontotemporal dementia with granulin mutationsThis is an older word used to describe a change in a specific gene leading to disease.  As not all mutations are bad, the word mutation has been replaced with the term “pathogenic variant” that d (FTD-GRN), and PBKR03 for Krabbe disease. Passage Bio plans to initiate clinical trials in GM1 in the first quarter of 2021 and in FTD-GRN and Krabbe disease in the first half of 2021.

Link to Full Release